GCaPPS: Genetic Cancer Prediction through Population Screening

Conditions

Genetic testing for BRCA founder mutations Cancer Malignant neoplasm of breast

Matthew Burnell, Faiza Gaba, Monika Sobočan, Rakshit Desai, Saskia C. Sanderson et al. (19 authors)

BJOG An International Journal of Obstetrics & Gynaecology2022-07-046 citations

Jewish cultural and religious factors and uptake of population‐based <i>BRCA</i> testing across denominations: a cohort study

Daniel Reisel, Matthew Burnell, Lucy Side, K Loggenberg, Sue Gessler et al. (18 authors)

BJOG An International Journal of Obstetrics & Gynaecology2021-11-115 citations

10.1111/1471-0528.16994

874 Uptake of population based BRCA-testing across Jewish denominations and affect of cultural and religious factors: a cohort study

Daniel Reisel, Matthew Burnell, Lucy Side, K Loggenberg, Sue Gessler et al. (17 authors)

2021-10-01

10.1136/ijgc-2021-esgo.557

Randomised trial of unselected BRCA testing in ashkenazi jews: long term outcomes and factors affecting uptake of testing

Ranjit Manchanda, Matthew Burnell, Faiza Gaba, Roopal Desai, Jane Wardle et al. (19 authors)

2019-11-01

10.1136/ijgc-2019-esgo.15

Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes.

Manchanda R, Burnell M, Gaba F, Desai R, Wardle J, Gessler S, Side L, Sanderson S, Loggenberg K, Brady AF, Dorkins H, Wallis Y, Chapman C, Jacobs C, Legood R, Beller U, Tomlinson I, Menon U, Jacobs I.

2019-09-1054 citations

10.1111/1471-0528.15905

81 Attitude towards and factors affecting uptake of population based BRCA testing in ashkenazi jews: a cohort study

Ranjit Manchanda, Matthew Burnell, Faiza Gaba, Saskia C. Sanderson, K Loggenberg et al. (18 authors)

2019-09-01

10.1136/ijgc-2019-igcs.81

Attitude towards and factors affecting uptake of population‐based<i><scp>BRCA</scp></i>testing in the Ashkenazi Jewish population: a cohort study

Ranjit Manchanda, Matthew Burnell, Faiza Gaba, Saskia C. Sanderson, K Loggenberg et al. (18 authors)

BJOG An International Journal of Obstetrics & Gynaecology2019-02-1533 citations

10.1111/1471-0528.15654

Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations.

Manchanda R, Burnell M, Loggenberg K, Desai R, Wardle J, Sanderson SC, Gessler S, Side L, Balogun N, Kumar A, Dorkins H, Wallis Y, Chapman C, Tomlinson I, Taylor R, Jacobs C, Legood R, Raikou M, McGuire A, Beller U, Menon U, Jacobs I.

2016-03-1841 citations

10.1136/jmedgenet-2015-103740

Abstract IS01: Brca testing in high-risk populations

Ranjit Manchanda

Clinical Cancer Research2015-08-15

10.1158/1557-3265.ovcasymp14-is01

Interventions

10,000 volunteers will be recruited in total

this number includes a pilot phase of 1,000 volunteers in the first year. This is a randomised controlled trial comparing a systematic population based approach to genetic testing for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: This is a healthy volunteer trial for Ashkenazi Jewish men and women. Inclusion criteria include: 1. Individuals over 18 years 2. Ashkenazi Jewish ethnicity (based on self-reported history of 4 Ashkenazi Jewish grandparents)

Exclusion criteria

Exclusion criteria: 1. Known BRCA mutation in an individual 2. First degree relative (FDR) of an individual with known BRCA mutation 3. Individuals who have already undergone BRCA founder mutation (FM) testing

Design outcomes

Primary

Measure	Time frame
1. Number of founder mutations (FM) detected, assessed by the genetic test result 2. Acceptability 2.1. Perception, attitudes towards BRCA1/2 testing: benefits, risks, limitations; cultural/religious influences; interest and intention, assessed by the baseline questionnaire and post-counselling assessment questionnaire 2.2. Satisfaction with counselling: Genetic Counselling Satisfaction Scale (GCSS), assessed as part of post-counselling assessment questionnaire and exit questionnaire (for those declining testing after counselling) 2.3. Uptake of testing 2.4. Reasons for declining testing, assessed by the exit questionnaire (for those declining testing after counselling) 3. Psychological impact, assessed by the baseline questionnaire, Follow-up Questionnaires 1, 2 and 3. These included the following: 3.1. Hospital Anxiety and Depression Scale (HADS): General well being, depression and anxiety 3.2. Short Form 12 (SF12): Psychological Quality of life (QoL) tool 3.3. Health Anxiety Inventory (HAI) 3.4. Multidimensional Impact of Cancer Risk Assessment (MICRA). This measure is used in Follow-up Questionnaires 1, 2 and 3 to assess the impact of test result 4. Uptake of screening and preventive strategies. Behavioural outcomes assessed by the baseline questionnaire, Follow-up Questionnaires 2 and 3. They included the following assessments: 4.1. Lifestyle behaviours (diet, exercise, alcohol, vitamins, etc.) 4.2. Cancer screening behaviours 4.3. Prophylactic surgery and chemoprevention 5. Health economics will be assessed by the baseline questionnaire, Follow-up Questionnaires 1, 2 and 3. This will involve within trial analysis of the counselling, screening and preventive strategies undertaken as well as modelling to estimate resource imp	—

Measure

Time frame

1. Number of founder mutations (FM) detected, assessed by the genetic test result 2. Acceptability 2.1. Perception, attitudes towards BRCA1/2 testing: benefits, risks, limitations; cultural/religious influences; interest and intention, assessed by the baseline questionnaire and post-counselling assessment questionnaire 2.2. Satisfaction with counselling: Genetic Counselling Satisfaction Scale (GCSS), assessed as part of post-counselling assessment questionnaire and exit questionnaire (for those declining testing after counselling) 2.3. Uptake of testing 2.4. Reasons for declining testing, assessed by the exit questionnaire (for those declining testing after counselling) 3. Psychological impact, assessed by the baseline questionnaire, Follow-up Questionnaires 1, 2 and 3. These included the following: 3.1. Hospital Anxiety and Depression Scale (HADS): General well being, depression and anxiety 3.2. Short Form 12 (SF12): Psychological Quality of life (QoL) tool 3.3. Health Anxiety Inventory (HAI) 3.4. Multidimensional Impact of Cancer Risk Assessment (MICRA). This measure is used in Follow-up Questionnaires 1, 2 and 3 to assess the impact of test result 4. Uptake of screening and preventive strategies. Behavioural outcomes assessed by the baseline questionnaire, Follow-up Questionnaires 2 and 3. They included the following assessments: 4.1. Lifestyle behaviours (diet, exercise, alcohol, vitamins, etc.) 4.2. Cancer screening behaviours 4.3. Prophylactic surgery and chemoprevention 5. Health economics will be assessed by the baseline questionnaire, Follow-up Questionnaires 1, 2 and 3. This will involve within trial analysis of the counselling, screening and preventive strategies undertaken as well as modelling to estimate resource imp

—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

England, United Kingdom

Outcome results

None listed